Design, synthesis, and structure-activity-relationship of tetrahydrothiazolopyridine derivatives as potent smoothened antagonists

European Journal of Medicinal Chemistry

Volumn 89, Issue , 2015, Pages 721-732

  Ma, Haikuo ^a   Lu, Wenfeng ^a   Sun, Zhijian ^b   Luo, Lusong ^b   Geng, Delong ^a   Yang, Zhaohui ^a   Li, Enqin ^a   Zheng, Jiyue ^a   Wang, Meiyu ^a   Zhang, Hongjian ^a   Yang, Shilin ^a   Zhang, Xiaohu ^a  

^a SOOCHOW UNIVERSITY   (China)

^b BeiGene   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1-(5-(5'-CHLORO-3,5-DIMETHYL-(2,4'-BIPYRIDIN)-2'-YL)-4,5,6,7-TETRAHYDROTHIAZOLO(5,4-C)PYRIDIN-2-YL)PIPERIDIN-4-OL; G PROTEIN COUPLED RECEPTOR; PYRIDINE DERIVATIVE; SMO PROTEIN, HUMAN; THIAZOLE DERIVATIVE;

3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG DESIGN; DRUG EFFECTS; HUMAN; MALE; METABOLISM; MOUSE; RAT; SIGNAL TRANSDUCTION; SOLUBILITY; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; HUMANS; MALE; MICE; MOLECULAR STRUCTURE; NIH 3T3 CELLS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; SOLUBILITY; STRUCTURE-ACTIVITY RELATIONSHIP; THIAZOLES;

EID: 84908667785     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2014.11.006     Document Type: Article

References (54)

1. M. Varjosalo J. Taipale Hedgehog: functions and mechanisms Genes Dev. 22 2008 2454 2472
2. J. Jiang C.C. Hui Hedgehog signaling in development and cancer Dev. Cell 15 2008 801 812
3. P.W. Ingham The patched gene in development and cancer Curr. Opin. Genet. Dev. 8 1998 88 94
4. J. Xie M. Murone S.M. Luoh A. Ryan Q. Gu C. Zhang J.M. Bonifas C.W. Lam M. Hynes A. Goddard A. Rosenthal E.H. Epstein Jr. F.J. de Sauvage Activating smoothened mutations in sporadic basal-cell carcinoma Nature 391 1998 90 92
5. S.J. Scales F.J. de Sauvage Mechanisms of hedgehog pathway activation in cancer and implications for therapy Trends Pharmacol. Sci. 30 2009 303 312
6. L. Yang G. Xie Q. Fan J. Xie Activation of the hedgehog-signaling pathway in human cancer and the clinical implications Oncogene 29 2010 469 481
7. J.M. Ng T. Curran The hedgehog's tale: developing strategies for targeting cancer Nat. Rev. Cancer 11 2011 493 501
8. S. Peukert K. Miller-Moslin Small-molecule inhibitors of the hedgehog signaling pathway as cancer therapeutics ChemMedChem 5 2010 500 512
9. Y. Li M.Y. Maitah A. Ahmad D. Kong B. Bao F.H. Sarkar Targeting the hedgehog signaling pathway for cancer therapy Expert Opin. Ther. Targets 16 2012 49 66
10. J.I. Yun H.R. Kim H. Park S.K. Kim J. Lee Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer Arch. Pharm. Res. 35 2012 1317 1333
11. M.K. Hadden Hedgehog pathway inhibitors: a patent review (2009-present) Expert Opin. Ther. Pat. 23 2013 345 361
12. D. Amakye Z. Jagani M. Dorsch Unraveling the therapeutic potential of the hedgehog pathway in cancer Nat. Med. 19 2013 1410 1422
13. M. Ruat L. Hoch H. Faure D. Rognan Targeting of smoothened for therapeutic gain Trends Pharmacol. Sci. 35 2014 237 246
14. M.K. Cooper J.A. Porter K.E. Young P.A. Beachy Teratogen-mediated inhibition of target tissue response to Shh signaling Science 280 1998 1603 1607
15. J.K. Chen J. Taipale M.K. Cooper P.A. Beachy Inhibition of hedgehog signaling by direct binding of cyclopamine to Smoothened Genes Dev. 16 2002 2743 2748
16. M.R. Tremblay M. Nevalainen S.J. Nair J.R. Porter A.C. Castro M.L. Behnke L.C. Yu M. Hagel K. White K. Faia L. Grenier M.J. Campbell J. Cushing C.N. Woodward J. Hoyt M.A. Foley M.A. Read J.R. Sydor J.K. Tong V.J. Palombella K. McGovern J. Adams Semisynthetic cyclopamine analogues as potent and orally bioavailable hedgehog pathway antagonists J. Med. Chem. 51 2008 6646 6649
17. M.R. Tremblay A. Lescarbeau M.J. Grogan E. Tan G. Lin B.C. Austad L.C. Yu M.L. Behnke S.J. Nair M. Hagel K. White J. Conley J.D. Manna T.M. Alvarez-Diez J. Hoyt C.N. Woodward J.R. Sydor M. Pink J. MacDougall M.J. Campbell J. Cushing J. Ferguson M.S. Curtis K. McGovern M.A. Read V.J. Palombella J. Adams A.C. Castro Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926) J. Med. Chem. 52 2009 4400 4418
18. H. Ma H.Q. Li X. Zhang Cyclopamine, a naturally occurring alkaloid, and its analogues may find wide applications in cancer therapy Curr. Top. Med. Chem. 13 2013 2208 2215
19. Infinity Stops Phase 2 Trials of Saridegib in Chondrosarcoma and Myelofibrosis January 18, 2012 Infinity Pharmaceuticals Press Release http://phx.corporate-ir.net/phoenix.zhtml?cCombining double low line121941&pCombining double low lineirol-newsArticle&IDCombining double low line1705831&highlightCombining double low line
20. Novartis Investigational Compound LDE225 Met Primary Endpoint in Pivotal Trial for Patients with Advanced Basal Cell Carcinoma February 19, 2014 Novartis Press Release http://www.novartis.com/newsroom/media-releases/en/2014/1762942.shtml
21. Pivotal Data for Novartis' Investigational Compound LDE225 Show Marked Tumor Responses in Advanced Basal Cell Carcinoma June 01, 2014 Novartis Press Release http://www.novartis.com/newsroom/media-releases/en/2014/1789711.shtml
22. K. Miller-Moslin S. Peukert R.K. Jain M.A. McEwan R. Karki L. Llamas N. Yusuff F. He Y. Li Y. Sun M. Dai L. Perez W. Michael T. Sheng H. Lei R. Zhang J. Williams A. Bourret A. Ramamurthy J. Yuan R. Guo M. Matsumoto A. Vattay W. Maniara A. Amaral M. Dorsch J.F. Kelleher 3rd 1-Amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity J. Med. Chem. 52 2009 3954 3968
23. N. Mahindroo C. Punchihewa N. Fujii Hedgehog-Gli signaling pathway inhibitors as anticancer agents J. Med. Chem. 52 2009 3829 3845
24. K.D. Robarge S.A. Brunton G.M. Castanedo Y. Cui M.S. Dina R. Goldsmith S.E. Gould O. Guichert J.L. Gunzner J. Halladay W. Jia C. Khojasteh M.F. Koehler K. Kotkow H. La R.L. Lalonde K. Lau L. Lee D. Marshall J.C. Marsters Jr. L.J. Murray C. Qian L.L. Rubin L. Salphati M.S. Stanley J.H. Stibbard D.P. Sutherlin S. Ubhayaker S. Wang S. Wong M. Xie GDC-0449-A potent inhibitor of the hedgehog pathway Bioorg. Med. Chem. Lett. 19 2009 5576 5581
25. B.S. Lucas W. Aaron S. An R.J. Austin M. Brown H. Chan A. Chong R. Hungate T. Huang B. Jiang M.G. Johnson J.A. Kaizerman G. Lee D.L. McMinn J. Orf J.P. Powers M. Rong M.M. Toteva C. Uyeda D. Wickramasinghe G. Xu Q. Ye W. Zhong Design of 1-piperazinyl-4-arylphthalazines as potent smoothened antagonists Bioorg. Med. Chem. Lett. 20 2010 3618 3622
26. S. Malancona S. Altamura G. Filocamo O. Kinzel J.I. Hernando M. Rowley R. Scarpelli C. Steinkuhler P. Jones Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclopropyl] -N -(1-phenyl-1H-pyrazol-5-yl)hexahydroimid azo[1,5-a]pyrazine-7(1H)-carboxamide), a potent smoothened antagonist for use in hedgehog pathway dependent malignancies, part 1 Bioorg. Med. Chem. Lett. 21 2011 4422 4428
27. O. Kinzel A. Alfieri S. Altamura M. Brunetti S. Bufali F. Colaceci F. Ferrigno G. Filocamo M. Fonsi P. Gallinari S. Malancona J.I. Hernando E. Monteagudo M.V. Orsale M.C. Palumbi V. Pucci M. Rowley R. Sasso R. Scarpelli C. Steinkuhler P. Jones Identification of MK-5710 ((8aS)-8a-methyl-1,3-dioxo-2-[(1S,2R)-2-phenylcyclo-propyl] -N -(1-phenyl-1H-pyrazol-5-yl)hexahydro-imidazo[1,5-a]pyrazine-7(1H)-carbox amide), a potent smoothened antagonist for use in hedgehog pathway dependent malignancies, part 2 Bioorg. Med. Chem. Lett. 21 2011 4429 4435
28. M.L. Brown W. Aaron R.J. Austin A. Chong T. Huang B. Jiang J.A. Kaizerman G. Lee B.S. Lucas D.L. McMinn J. Orf M. Rong M.M. Toteva G. Xu Q. Ye W. Zhong M.R. Degraffenreid D. Wickramasinghe J.P. Powers R. Hungate M.G. Johnson Discovery of amide replacements that improve activity and metabolic stability of a bis-amide smoothened antagonist hit Bioorg. Med. Chem. Lett. 21 2011 5206 5209
29. S. Pan X. Wu J. Jiang W. Gao Y. Wan D. Cheng D. Han J. Liu N.P. Englund Y. Wang Discovery of NVP-LDE225, a potent and selective smoothened antagonist ACS Med. Chem. Lett. 1 2010 130 134
30. M.J. Munchhof Q. Li A. Shavnya G.V. Borzillo T.L. Boyden C.S. Jones S.D. LaGreca L. Martinez-Alsina N. Patel K. Pelletier Discovery of PF-04449913, a potent and orally bioavailable inhibitor of smoothened ACS Med. Chem. Lett. 3 2011 106 111
31. M. Betti G. Castagnoli A. Panico S. Sanna Coccone P. Wiedenau Development of a scalable route to the SMO receptor antagonist SEN794 Org. Process Res. Dev. 16 2012 1739 1745
32. S. Peukert F. He M. Dai R. Zhang Y. Sun K. Miller-Moslin M. McEwan B. Lagu K. Wang N. Yusuff A. Bourret A. Ramamurthy W. Maniara A. Amaral A. Vattay A. Wang R. Guo J. Yuan J. Green J. Williams S. Buonamici J.F. Kelleher 3rd M. Dorsch Discovery of NVP-LEQ506, a second-generation inhibitor of smoothened ChemMedChem 8 2013 1261 1265
33. F. Manetti H. Faure H. Roudaut T. Gorojankina E. Traiffort A. Schoenfelder A. Mann A. Solinas M. Taddei M. Ruat Virtual screening-based discovery and mechanistic characterization of the acylthiourea MRT-10 family as smoothened antagonists Mol. Pharmacol. 78 2010 658 665
34. A. Solinas H. Faure H. Roudaut E. Traiffort A. Schoenfelder A. Mann F. Manetti M. Taddei M. Ruat Acylthiourea, acylurea, and acylguanidine derivatives with potent hedgehog inhibiting activity J. Med. Chem. 55 2012 1559 1571
35. M. Xin J. Wen F. Tang C. Tu H. Shen X. Zhao The discovery of novel N-(2-pyrimidinylamino) benzamide derivatives as potent hedgehog signaling pathway inhibitors Bioorg. Med. Chem. Lett. 23 2013 6777 6783
36. Curis Announces FDA Approval of Erivedge(TM) (Vismodegib) Capsule as First Treatment for Advanced Basal Cell Carcinoma January 30, 2012 Curis Pharmaceuticals Press Release http://investors.curis.com/releasedetail.cfm?ReleaseIDCombining double low line643756
37. R.L. Yauch G.J. Dijkgraaf B. Alicke T. Januario C.P. Ahn T. Holcomb K. Pujara J. Stinson C.A. Callahan T. Tang J.F. Bazan Z. Kan S. Seshagiri C.L. Hann S.E. Gould J.A. Low C.M. Rudin F.J. de Sauvage Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma Science 326 2009 572 574
38. S. Buonamici J. Williams M. Morrissey A. Wang R. Guo A. Vattay K. Hsiao J. Yuan J. Green B. Ospina Q. Yu L. Ostrom P. Fordjour D.L. Anderson J.E. Monahan J.F. Kelleher S. Peukert S. Pan X. Wu S.M. Maira C. Garcia-Echeverria K.J. Briggs D.N. Watkins Y.M. Yao C. Lengauer M. Warmuth W.R. Sellers M. Dorsch Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma Sci. Transl. Med. 2 2010 51ra70
39. C. Wang H. Wu V. Katritch G.W. Han X.P. Huang W. Liu F.Y. Siu B.L. Roth V. Cherezov R.C. Stevens Structure of the human smoothened receptor bound to an antitumour agent Nature 497 2013 338 343
40. S.K. Nair S.P. Planken Pyridine-2-derivatives as Smoothened Receptor Modulators 2012 WO2012052948
41. A. Rohner M.E. Spilker J.L. Lam B. Pascual D. Bartkowski Q.J. Li A.H. Yang G. Stevens M. Xu P.A. Wells S. Planken S. Nair S. Sun Effective targeting of hedgehog signaling in a medulloblastoma model with PF-5274857, a potent and selective smoothened antagonist that penetrates the blood-brain barrier Mol. Cancer Ther. 11 2012 57 65
42. F. Lovering J. Bikker C. Humblet Escape from flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 52 2009 6752 6756
43. Y. Yang O. Engkvist A. Llinas H. Chen Beyond size, ionization state, and lipophilicity: influence of molecular topology on absorption, distribution, metabolism, excretion, and toxicity for druglike compounds J. Med. Chem. 55 2012 3667 3677
44. X. Zhang J.E. Tellew Z. Luo M. Moorjani E. Lin M.C. Lanier Y. Chen J.P. Williams J. Saunders S.M. Lechner S. Markison T. Joswig R. Petroski J. Piercey W. Kargo S. Malany M. Santos R.S. Gross J. Wen K. Jalali Z. O'Brien C.E. Stotz M.I. Crespo J.L. Diaz D.H. Slee Lead optimization of 4-acetylamino-2-(3,5-dimethylpyrazol-1-yl)-6-pyridylpyrimidines as A2A adenosine receptor antagonists for the treatment of Parkinson's disease J. Med. Chem. 51 2008 7099 7110
45. M.C. Lanier M. Moorjani Z. Luo Y. Chen E. Lin J.E. Tellew X. Zhang J.P. Williams R.S. Gross S.M. Lechner S. Markison T. Joswig W. Kargo J. Piercey M. Santos S. Malany M. Zhao R. Petroski M.I. Crespo J.L. Diaz J. Saunders J. Wen Z. O'Brien K. Jalali A. Madan D.H. Slee N-[6-amino-2-(heteroaryl)pyrimidin-4-yl]acetamides as A2A receptor antagonists with improved drug like properties and in vivo efficacy J. Med. Chem. 52 2009 709 717
46. C.A. Lipinski F. Lombardo B.W. Dominy P.J. Feeney Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25
47. W. Lu D. Geng Z. Sun Z. Yang H. Ma J. Zheng X. Zhang Scaffold hopping approach to a new series of smoothened antagonists Bioorg. Med. Chem. Lett. 24 2014 2300 2304
48. 2O Russ. J. Org. Chem. 47 2011 1498 1500
49. J. Taipale J.K. Chen M.K. Cooper B. Wang R.K. Mann L. Milenkovic M.P. Scott P.A. Beachy Effects of oncogenic mutations in smoothened and patched can be reversed by cyclopamine Nature 406 2000 1005 1009
50. J.K. Chen J. Taipale K.E. Young T. Maiti P.A. Beachy Small molecule modulation of smoothened activity Proc. Natl. Acad. Sci. U. S. A. 99 2002 14071 14076
51. B.Z. Stanton L.F. Peng N. Maloof K. Nakai X. Wang J.L. Duffner K.M. Taveras J.M. Hyman S.W. Lee A.N. Koehler J.K. Chen J.L. Fox A. Mandinova S.L. Schreiber A small molecule that binds hedgehog and blocks its signaling in human cells Nat. Chem. Biol. 5 2009 154 156
52. E. Petrova J. Rios-Esteves O. Ouerfelli J.F. Glickman M.D. Resh Inhibitors of hedgehog acyltransferase block sonic hedgehog signaling Nat. Chem. Biol. 9 2013 247 249
53. J. Wang J. Lu M.C. Bond M. Chem X.R. Ren H.K. Lyerly L.S. Barak W. Chen Identification of select glucocorticoids as smoothened agonists: potential utility for regenerative medicine Proc. Natl. Acad. Sci. U. S. A. 107 2010 9323 9328
54. J. Wang R.A. Mook Jr. J. Lu D.M. Gooden A. Ribeiro A. Guo L.S. Barak H.K. Lyerly W. Chen Identification of a novel smoothened-antagonist that potently suppressed hedgehog signaling Bioorg. Med. Chem. 20 2012 6751 6757.